Sigilon Therapeutics Introduces Scientific Advisory Board for Guiding Development of Afibromer(TM) Living Therapeutics

CAMBRIDGE, Mass., Oct. 16, 2017 -- (Healthcare Sales & Marketing Network)-- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the formation of a scientific advisor...Biopharmaceuticals, Personnel
Sigilon Therapeutics, Afibromer, living therapeutic implants